Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

VivoSim Labs, Inc. - Common Stock (NQ:VIVS)

0.3433 -0.0013 (-0.38%)
Streaming Delayed Price Updated: 9:31 AM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about VivoSim Labs, Inc. - Common Stock

< Previous 1 2 Next >
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
MissionIRNewsBreaks – VivoSim Labs, Inc. (NASDAQ: VIVS) Announces $4 Million Private Placement
Via Investor Brand Network
Topics Animal Testing
News headline image
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
Initial customer wins bring VivoSim’s human-relevant liver and GI testing to the world’s second-largest pharmaceutical market 
From VivoSim Labs, Inc.
Via GlobeNewswire
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
Thursday's session: top gainers and losers ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs) 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
VivoSim’s NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results 
From VivoSim Labs, Inc.
Via GlobeNewswire
Which stocks are moving before the opening bell on Wednesday? ↗
Via Chartmill
News headline image
VivoSim Announces Pricing of up to a $4 Million Public Offering
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial growth along the US East Coast, deepening VivoSim’s reach with... 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
Company produces thorough reference testing on Antibody Drug Conjugates, showing high correlation with clinical liver and intestinal toxicity and side effects 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
Why Is VIVS Stock Up 79% Today? ↗
VivoSims said on Friday that it has signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in China for its NAMKind human-based toxicology services. 
Via Stocktwits
Topics Animal Testing
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Check out the stocks that are attracting the most attention and driving market activity. ↗
Via Chartmill
Top movers analysis in the middle of the day on 2026-01-30: top gainers and losers in today's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China
JCBio appointed for Korea; Tekon Biotech appointed for China provide access to liver and small-intestine NAM screening with “molecules in, data out” speed and human relevance 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer
Distinguished drug-development and biomarker leader to advance NAMkind™ scientific strategy, translational insights, and next-generation toxicology platforms 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
These stocks are moving in today's session ↗
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Roadzen Inc. (NASDAQ: RDZN) Accelerates U.S. Expansion with Strategic Acquisition – Surges on Record Volume – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Alphabet Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Tuesday's session: top gainers and losers ↗
Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.